

**Arazlo Lotion Approved for Acne Vulgaris**

Ortho Dermatologics announces US Food and Drug Administration approval of Arazlo (tazarotene) Lotion 0.045% for the topical treatment of acne vulgaris in patients 9 years and older. Arazlo provides the efficacy expected of tazarotene in a lotion formulation that helps minimize dryness and irritation historically associated with retinoids. Arazlo is expected to be available for prescription in the first half of 2020. For more information, visit <https://ortho-dermatologics.com>.

**FDA Clears Lutronic LaseMD Ultra**

Lutronic receives US Food and Drug Administration clearance of Lutronic LaseMD Ultra, a 1927-nm nonablative fractional laser to treat lentigos, solar lentigos, ephelides, actinic keratoses, and other benign pigmented lesions in all skin types. Lutronic LaseMD Ultra offers 20 W of power to treat multiple areas quickly and an advanced graphical user interface for customizable outcomes. For more information, visit <https://us.aesthetic.lutronic.com>.

**18th World Congress on Cancers of the Skin**

The 18th World Congress on Cancers of the Skin will be held in Buenos Aires, Argentina, from June 24 to June 27, 2020. The event is organized by Colegio Ibero Latinoamericano de Dermatología (CILAD) and cosponsored by The Skin Cancer Foundation. For more information, visit <https://www.wccs2020.com/>.

**Wynzora Cream for Plaque Psoriasis**

MC2 Therapeutics announces Wynzora Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) has met its primary end point for its phase 3 trial in Europe in adult patients with plaque psoriasis. Wynzora Cream utilizes PAD Technology, which enables stability of both calcipotriene and betamethasone dipropionate in an aqueous cream formulation. It offers patients with plaque psoriasis a once-daily topical treatment that can be quickly absorbed into the skin, is not greasy, and is convenient for routine use. The US Food and Drug Administration accepted the New Drug Application seeking marketing approval for Wynzora Cream. The combination of clinical efficacy, favorable safety profile, and high convenience of Wynzora Cream demonstrated in clinical trials hold promise to increase treatment adherence and overall patient satisfaction in the real-world setting. For more information, visit <https://www.mc2therapeutics.com/>.

*If you would like your product included in Product News, please email a press release to the Editorial Office at [cutis@mdedge.com](mailto:cutis@mdedge.com).*